Andrea Park

Chicago

Deputy Editor, Fierce Medtech at Fierce Life Sciences

Freelance SEO Writer at Marie Claire

Featured in: Favicon

fiercelifesciences.com Favicon

yahoo.com (+6) Favicon

cbsnews.com Favicon

foxnews.com Favicon

insider.com Favicon

cbslocal.com + 79 more

Articles

TV drug ad spending continues upward climb, logging nearly 30% growth in Q1

1 week ago | fiercepharma.com | Andrea Park

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV commercials in the first quarter compared to the same period a year ago. Across the first three months of this year, according to iSpot.TV, drugmakers have spent a combined $729.4 million to air commercials for the top 10 brands, up from $567.3 million in the first quarter of 2024.
Apellis, AstraZeneca break down their #FierceMadness 2025 Drug Ad Tournament success

1 week ago | fiercepharma.com | Andrea Park

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition. The trophy ultimately went to Apellis, but both companies’ commercials racked up plenty of fans on the road to their championship match-up.
‘Saturday Night Live’ skewers drug ad tropes in Jon Hamm-led skit

1 week ago | fiercepharma.com | Andrea Park

If you ever find yourself doing outdoor hobbies in slow motion or bursting into a full-blown musical theater scene at the office, beware: You might be in a pharmaceutical ad. That’s the thesis of a new sketch that aired on “Saturday Night Live” this past weekend, in an episode hosted by actor Jon Hamm.
After Hetlioz’s rejection in jet lag disorder, Vanda sues FDA for right to promote off-label use

1 week ago | fiercepharma.com | Andrea Park

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda Pharmaceuticals is pursuing a new route to establish the drug in the space. Hetlioz was approved more than a decade ago for non-24-hour sleep-wake disorder, a circadian rhythm condition, and expanded its label in 2020 to target nighttime sleep disorders associated with the rare neurodevelopmental disorder Smith-Magenis syndrome.
Q1 biopharma layoff trends, plus expectations for Q2

1 week ago | fiercebiotech.com | Ayla Ellison |Gabrielle Masson |Andrea Park

Welcome! In order to deliver a personalized and enhanced site navigation, we store information on how you use the site. We want you to know that we respect your privacy and your right to control how we collect and use your personal data. For more information, please see the Questex Privacy PolicyManage my cookie preferences
Alzheimer’s Association expands PSA campaign about early dementia signs to focus on Black Americans

2 weeks ago | fiercepharma.com | Andrea Park

After the success of a public service advertisement campaign aimed at improving recognition of the early signs of Alzheimer’s disease in Hispanic and Latino communities, the Alzheimer’s Association is expanding the PSAs’ reach to another group disproportionately affected by the disease.
Annexon rolls out Guillain-Barré awareness campaign for HCPs

2 weeks ago | fiercepharma.com | Andrea Park

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. Alongside a clinical data presentation at the American Academy of Neurology’s annual meeting, which wrapped up Wednesday, Annexon also debuted a new awareness campaign aimed at educating healthcare professionals about GBS.
Rocket boosts preparations for gene therapy launch with new commercial chief from J&J, AstraZeneca

2 weeks ago | fiercepharma.com | Andrea Park

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team. The biotech on Monday appointed Sarbani Chaudhuri as its new chief commercial and medical affairs officer, according to a filing with the U.S. Securities and Exchange Commission. Chaudhuri comes to Rocket from Johnson & Johnson Innovative Medicine, where she served at the VP level as head of hematology in the global commercial strategy organization.
Novo’s Wegovy, J&J’s Tremfya step up TV ad spending amid March Madness tournament

2 weeks ago | fiercepharma.com | Andrea Park

Last year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading the pair of immunology meds to take the full-year title for the third year in a row. 2025, however, is already off to a very different start.
‘SNL’ star Kenan Thompson serves up a new campaign for Phathom’s Voquezna

2 weeks ago | fiercepharma.com | Andrea Park

Funnyman Kenan Thompson is opening up about the not-so-funny experience of living with gastroesophageal reflux disease (GERD). In a new campaign for Phathom Pharmaceuticals’ GERD med Voquezna, Thompson—who takes Voquezna to ease heartburn caused by non-erosive GERD, according to the partnership announcement this week—speaks for the first time about his diagnosis to raise awareness of the disease and encourage people with GERD to consult a doctor about possible treatments.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →